Skip to main content

News

Filter by:
  • 20231129_SCKCEN_CRF_5
    28 May '24

    Discover a new dimension of cancer treatment

    SCK CEN launches a podcast about Targeted Radionuclide Therapy  

    Discover a new dimension of cancer treatment with the SCK CEN podcast: 'R.E.A.C.T. - Radionuclide Enables Alternative Cancer Treatment'. This podcast explores the power of atoms and their potential to redefine cancer treatment once and for all. Listen and delve into groundbreaking research with promising perspectives. The first episode is now online - during European Cancer Week! 

    Quickly head to Spotify and listen to the podcast.

  • 20240229_SCKCEN-Impact medical discharge on environment-Water treatment plant.jpg
    29 February '24

    SCK CEN sheds light on the long-term effects of radioisotopes in rivers and enhances protection for humans and nature

    New method for assessing the impact of medical radiopharmaceuticals on the environment

    When you receive a diagnosis or treatment involving medical radioisotopes in the hospital, a small amount of radioactivity ends up in the sewer after your restroom visit. But what if we use more of these medical substances in the future? Will the existing protective measures still be effective? Research conducted by SCK CEN, the Belgian Nuclear Research Center, provides a way to assess the safety of these discharges. As part of the European SINFONIA project, experts proactively investigated the potential long-term effects of hospital wastewater on the environment and human health. The result is a new methodology for more accurately assessing the possible impact on people, animals, and the environment. “This approach is particularly useful for predicting the impact of future new medications on the ecosystem and proactively adjusting regulations as needed,” emphasizes Jordi Vives i Batlle, an expert in impact studies at SCK CEN.

  • SCK  CEN  -  Lancering Pantera (2022)
    13 February '24

    PanTera signs agreement with Bayer for the supply of actinium-225

    Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients

    PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of 2024.